All In Biotech

Drug Trial Radar · NCT04411472

(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI

A DB, Placebo-Controlled, Two-Arm Parallel-Group, Phase 3 RCT to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatment of Patients With SA-AKI

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 676 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

676

Actual

Start

Nov 2, 2020

Primary completion

Aug 18, 2022

Study completion Aug 18, 2022

Sponsor

Lead sponsor
AM-PharmaIndustry
Sponsor type
Industry
First posted
Jun 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical phase 3 study to investigate the effect of recAP on 28 day mortality in patients admitted to the ICU with acute kidney injury that is caused by sepsis. The study has three distinct SA-AKI trial populations: 1. The main trial population: Patients with a pre-AKI reference eGFR ≥45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization. 2. A 'moderate' CKD population: Patients with a pre-AKI reference eGFR ≥25 and \<45 mL/min/1.73 m2 and no proven or suspected SARS-CoV-2 at time of randomization. 3. A Corona Virus Disease 2019 (COVID-19) population: Patients with proven or suspected SARS-CoV-2 at time of randomization with or without 'moderate' CKD. For patients in this population, COVID-19 should be the main cause of SA-AKI. In the main study population approximately 1400 patients will be enrolled and in the two cohorts with moderate CKD and COVID-19 each up to 100 patients. There are two arms in the study, one with active treatment and one with an inactive compound (placebo). Treatment is by 1 hour intravenous infusion, for three days. Patients are followed up for 28 days to see if there is an improvement on mortality, and followed for 90 and 180 days for mortality and other outcomes e.g. long-term kidney function and quality of life.

Conditions

  • Acute Kidney Injury Due to Sepsis

Interventions

  • Recombinant human alkaline phosphataseBiological

    patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28-day All-cause Mortality: Main Trial PopulationTime frame: 28 days
  2. 28-day All-cause Mortality: Moderate Chronic Kidney Disease PopulationTime frame: 28 days
  3. 28-day All-cause Mortality: COVID-19 PopulationTime frame: 28 days

Locations

122 sites in 15 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • The George Washington University Medical Faculty Associates - Anesthesiology

    Washington D.C., District of Columbia

  • Emory Clinical Cardiovascular Research Institute

    Atlanta, Georgia

  • Glenbrook Hospital

    Glenview, Illinois

  • NorthShore Medical Group - Bannockburn

    Highland Park, Illinois

  • University of Kentucky College of Medicine (UKCM)

    Lexington, Kentucky

  • Regions Hospital

    Saint Paul, Minnesota

  • University of New Mexico School of Medicine

    Albuquerque, New Mexico

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • University of Cincinnati Cancer Institute

    Cincinnati, Ohio

  • The Ohio State University - Dorothy M. Davis Heart and Lung Research Institute

    Columbus, Ohio

  • UPMC CancerCenter at Magee - Womens Hospital

    Pittsburgh, Pennsylvania

  • UPMC Presbyterian

    Pittsburgh, Pennsylvania

  • University of Virginia Health System

    Charlottesville, Virginia

  • Froedtert & the Medical College of Wisconsin Froedtert Hospital

    Milwaukee, Wisconsin

  • Flinders Medical Centre

    Bedford Park, Australia

  • Bendigo Hospital

    Bendigo, Australia

  • Footscray Hospital

    Footscray, Australia

  • Austin Hospital

    Melbourne, Australia

  • John Hunter Hospital

    New Lambton Heights, Australia

  • Sunshine Hospital ICU - Western Hospital

    Saint Albans, Australia

  • Gold Coast University Hospital (GCUH)

    Southport, Australia

  • Medizinische Universitaet Graz - Klinik fuer Innere Medizin

    Graz, Austria

  • Medizinische Universitaet Innsbruck - Universitaetsklinik fuer Innere Medizin I

    Innsbruck, Austria

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Centre Hospitalier Universitaire Brugmann

    Brussels, Belgium

  • Centre Hospitalier Universitaire (CHU) de Charleroi - Hopital Civil Marie Curie

    Charleroi, Belgium

  • Ziekenhuis Oost-Limburg

    Genk, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitair Ziekenhuis Brussel

    Jette, Belgium

  • Hôpital de JOLIMONT

    La Louvière, Belgium

  • Clinique Saint-Pierre- Ottignies

    Ottignies, Belgium

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Belgium

  • CHU UCL Namur - Mont-Godinne

    Yvoir, Belgium

  • Peter Lougheed Centre

    Calgary, Canada

  • Foothills Medical Centre

    Calgary, Canada

  • Rockyview General Hospital

    Calgary, Canada

  • Alberta Health Services - South Health Campus Hospital

    Calgary, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Canada

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.